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Abstract
Summary Vitamin D deficiency is very common in non-
western immigrants. Inthis randomizedclinical trial, vitamin
D 800 IU/day or 100,000 IU/3 months were compared with
advised sunlight exposure. Vitamin D supplementation was
more effective than advised sunlight exposure in improving
vitamin D status and lowering parathyroid hormone levels.
Introduction Vitamin D deficiency (25-hydroxyvitamin D
[25(OH)D]<25 nmol/l) is common among non-western
immigrants. It can be treated with vitamin D supplementa-
tion or sunlight exposure.
Methods To determine whether the effect of vitamin D3
supplementation (daily 800 IU or 100,000 IU/3 months) or
sunlight exposure advice is similar with regard to serum
25(OH)D and parathyroid hormone (PTH) concentrations.
Randomized clinical trial in 11 general practices in The
Netherlands. Non-western immigrants, aged 18–65 years
(n=232) and serum 25(OH)D<25 nmol/l were randomly
assigned to supplementation (daily 800 IU or 100,000 IU/
3 months) or advice for sunlight exposure for 6 months
(March–September). Blood samples were collected at
baseline, during treatment (3 months, 6 months), and at
follow-up (12 months). Statistical analysis was performed
with multilevel regression modelling.
Results The intention-to-treat analysis included 211 per-
sons. Baseline serum 25(OH)D was 22.5±11.1 nmol/l.
After 6 months, mean serum 25(OH)D increased to
53 nmol/l with 800 IU/day, to 50.5 nmol/l with
100,000 IU/3 months, and to 29.1 nmol/l with advised
sunlight exposure (supplementation vs sunshine p<0.001).
Serum PTH decreased significantly in all groups after
3 months, more in the supplementation groups than in the
advised sunlight group (p<0.05). There was no significant
effect on physical performance and functional limitations.
Conclusion Vitamin D supplementation is more effective
than advised sunlight exposure for treating vitamin D
deficiency in non-western immigrants.
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Vitamin D deficiency is common among moderately and
heavily pigmented immigrants living in Europe [1–6] and
other continents. Recent studies in the Netherlands have
shown that 40% to 80% of non-western immigrants are
vitamin D-deficient (serum 25-hydroxyvitamin D, 25(OH)
D<25 nmol/l) [7–9]. Approximately 1.7 million non-
western immigrants are currently living in the Netherlands
(http://statline.cbs.nl/StatWeb/start.asp, accessed 12 March
2008), suggesting that at least 680,000 of these immigrants
are vitamin D-deficient.
During exposure to sunshine, UV photons (290−315 nm)
penetrate the epidermis and photolyse 7-dehydrocholesterol
(provitamin D3) to previtamin D3. Melanin effectively
filters the UV radiation that enters the epidermis and limits
the synthesis of vitamin D3 [10]. The more melanin there is
in the skin, the lower the amount of previtamin D3 that is
synthesized by a given dose of UVB. In heavily pigmented
individuals, only a fraction of the available UVB reaches
the 7-dehydrocholesterol in cells for vitamin D3 synthesis
[11]. Besides skin type, low sunshine exposure, covering of
the skin, use of sunscreens, aging, and low dietary vitamin
D and calcium intake contribute to a deficient vitamin D
status [12]. The fact that, in the Netherlands, only
margarine, which is not regularly consumed by non-
western immigrants, is fortified with vitamin D (3 IU
per gram) also adds to the risk for developing vitamin
D deficiency.
Vitamin D deficiency initially causes an increase of
the serum parathyroid hormone (PTH) concentration [1],
which results in bone loss, followed by a defective
mineralization of the newly formed bone (the osteoid
tissue), resulting in osteomalacia in the long term [5, 12,
13] .H o w e v e r ,t h ed e g r e eo fP T Hi n c r e a s em a yb ev e r y
different, from almost none to frank secondary hyper-
parathyroidism. With regard to musculoskeletal health,
studies have shown that poor vitamin D status (low
serum 25(OH)D) is associated with poor physical
performance [14–21], weakness of the proximal muscles
[22], and pain [23], but other studies did not find this
association [24, 25]. Several clinical trials have demon-
strated that vitamin D supplementation can decrease
fracture risk [12, 16]
Vitamin D deficiency can be treated by sunshine
exposure or vitamin D supplementation, either daily or
with greater intervals such as monthly or every 3 months.
However, within non-western immigrants, the efficacy of
those interventions on both vitamin D status and clinical
outcomes has never been compared. Social and cultural
habits may hamper exposure to sunshine in some groups
of immigrants. Compliance is another issue that should
be addressed.
The principal aim of this study was to determine whether
the effects of supplementation with vitamin D3 (daily
800 IU or 100,000 IU/3 months) or advised sunlight
exposure are similar with regard to serum 25(OH)D, PTH,
and alkaline phosphatase concentrations. The second aim
was to investigate whether the effects of the different
interventions are comparable with respect to three clinical
outcomes: physical performance tests, functional limita-
tions, and pain.
Methods
Study design and setting
The study was designed as a randomized controlled trial,
comparing the effect of supplementation with vitamin
D3, either a daily dose or an equivalent dose once every
3 months, with the effect of advice for sunlight exposure.
The active study treatment was administered during
6m o n t h s ,b e t w e e nM a r c ha n dS e p t e m b e r ,a st h e s ea r e
the months where sunlight results in vitamin D synthesis
in the skin at the latitude of the Netherlands (52ºN). Data
and blood samples were collected at baseline, during
treatment (at 3 months and 6 months), and during the
follow-up period (at 12 months). After eligibility was
verified, written informed consent was obtained. The
study was approved by the Medical Ethics Committee of
the VU University Medical Center. The trial has been
registered at the Dutch Clinical Trials Register (NRT;
ISRCTN58849315, http://www.trialregister.nl).
Study participants
Participants were non-western immigrants aged 18−65 years
with documented vitamin D deficiency (serum 25-OHD<
25 nmol/l, according to analysis made by local laboratory)
within 3 months before the start of the study. Partic-
ipants were recruited from 10 collaborating general
practices (GPs) (Amsterdam, The Hague, Haarlem,
Amersfoort) and one university clinic (Amsterdam) in
The Netherlands. Participants were recruited between
January and March 2004 and between January and
March 2005 by their general practitioners. Participants
were invited at their local GPs or the university clinic
during the study for the assessments and blood
sampling. We anticipated a high risk to lose participants
during the study if they had to travel to the hospital.
Potential participants were excluded if they (a) had been
treated for vitamin D deficiency within the last
3 months, (b) were immobile, or (c) had diseases
interfering with measurements (e.g., psychiatric disor-
ders, rheumatoid arthritis). Research nurses and GP
874 Osteoporos Int (2011) 22:873–882assistants received a central training regarding random-
ization, medication, and measurements.
Treatment
An independent statistician, not involved in recruitment of
patients, generated a random list that was stratified for
general practitioner and sex by permutation of randomized
blocks, with a block size of 6. A researcher opened
prepared, numbered, opaque, sealed envelopes containing
the treatment codes. The participants were randomized into
three groups: advice for direct sunlight exposure for at least
one half hour per day, vitamin D3 800 IU/day (two tablets
of 400 IU), or vitamin D3 100,000 IU once in 3 months
(four capsules of 25,000 IU). The participants in the
sunlight group had to keep a diary on sunlight exposure.
Participants in the 800 IU group had to return the
supplement bottle at the next appointment, and participants
of the 100,000 IU group took the vitamin D under
supervision. The vitamin D3 was provided for 6 months,
as long as the sunlight is effective in the Netherlands, i.e.,
the end of September. The high-dose vitamin D3 group
received 100,000 IU at baseline and at 3 months.
Outcomes
Primary outcomes: biochemistry
Blood samples were obtained at baseline (in fasting
state), 3 months, 6 months (in fasting state), and
12 months. The blood was immediately centrifuged and
the plasma or serum was used immediately or frozen for
later measurements. Serum calcium, phosphate, albumin,
creatinine, and alkaline phosphatase were measured
according to routine laboratory methods in a local
laboratory. For serum 25(OH)D and PTH, serum was
kept frozen at −20°C until analysis at the university
laboratory. All samples from one person were analyzed
in the same run in order to minimize variation. Serum 25
(OH)D was analyzed using radioimmunoassay (Diasorin,
Stillwater, MN, USA). The intra-assay coefficient of
variation was 12%, 9%, and 7% for, respectively, 8, 25,
and 100 nmol/l. The inter-assay coefficient of variation
was 20%, 10%, and 8% for, respectively, 8, 30, and
65 nmol/l. The lower detection limit of the assay was
5 nmol/l. Serum PTH was analyzed using immunoradio-
metricassay (Luminescence, Immulite 2500, DPC, Los
Angeles, CA, USA). The intra-assay coefficient of
variation was 3% for the 0.3−20 pmol/l range, and 4%
for >20 pmol/l. The inter-assay coefficient of variation
was 7% of the total range. The lower detection limit of
the assay was 0.3 pmol/l.
Clinical outcomes
Both physical performance tests to measure muscle
strength and questionnaires to assess functional limita-
tions in daily activities and pain were used.
Physical performance tests
These tests were done according to the manual of the
Longitudinal Aging Study Amsterdam (LASA), and the
scores relate to falls and fractures [26]. Handgrip strength
was used as an indicator of muscle strength (kg) and was
assessed using a hand grip strength dynamometer (Takei
TKK 5001, Takei Scientific Instruments, Tokyo, Japan).
Subjects stood with arms and wrists stretched out at the
sides of the body. They were asked to perform two
maximum force trials with each hand. For the final scores,
the maximum value, whether left or right hand, was used.
The inter-observer coefficient of variation was 5%. Sec-
ondly, chair stands test was used as an indicator of proximal
muscle strength. To test the ability to rise from a chair,
persons were asked to fold their arms across their chest and
to stand up and sit down five times from a standard kitchen
chair. Time taken to perform the task was measured
(seconds).
Functional limitations
Functional limitations were assessed with a questionnaire
concerning the degree of difficulty of the following three
activities of daily living: getting up from a chair,
climbing the stairs, and walking several hundred meters.
In these daily activities, the muscles of the upper legs are
addressed in particular. The scores per activity ranged
from 0 (without difficulty) to 4 (help is needed). Both
summed scores (0−12) and dichotomized scores
(0 = without difficulty or little difficulty, 1 = great
difficulty or help needed) were analyzed. These questions
were adapted from the Longitudinal Aging Study
Amsterdam [27] and were used in a prior survey in the
Netherlands among non-western immigrants [8].
Pain
Six questions were asked to assess pain. To assess proximal
muscle pain, the following two questions were asked: “Do
you have muscle pain in your upper legs, while walking a
small distance?” and “Do you have muscle pain in your
upper legs, while sitting on a chair?” Scores were
dichotomized into 0 “no pain” and 1 “yes” (sometimes or
always). Participants were asked if they had shoulder pain
during the last 2 weeks and how often they experienced
shoulder pain per month. Participants were also asked if
Osteoporos Int (2011) 22:873–882 875they experienced headaches during the last 2 weeks and the
average number of headache episodes a year.
Potential confounders
The potential confounders, gender, age (at baseline), body
mass index (BMI), and time of sunshine exposure (self-
reported minutes per week) were included into the
statistical analyses. Age was measured at baseline. BMI
was calculated as weight (kg)/height (m
2). Body weight
was measured without heavy clothes (e.g., jacket, coat) and
shoes, using a calibrated balance beam scale. Body height
was measured with a stadiometer, without shoes. BMI was
categorized into three groups: underweight (BMI<20 kg/
m




2). Information on sunlight
exposure was based on self-report. To estimate the daily
sunlight exposure, the respondents were asked to indicate
time of day (before 12 am, 12−15 pm, 15−18 pm, and after
18 pm) and time (minutes) spent outdoors during summer
months on weekdays and weekend days, respectively.
Respondents were also asked to indicate areas of uncovered
skin (face, hands, forearms, upper arms, lower legs, upper
legs, upper abdomen, and back) during summer months on
weekdays and weekend days.
Statistical analysis
Differences in demographic and baseline variables may
occur by chance in a randomized study design. The three
intervention-groups were first compared on these varia-
bles. Second, data analyses were performed based on
treatment assignment according to the intention-to-treat
principle. Longitudinal changes were investigated using
the multilevel program MLwiN 2.02 [28–30]. Linear
regression was used to investigate changes in serum 25
(OH)D and PTH, physical functioning, and functional
limitations. The interaction between intervention and BMI
was tested in the relationship between intervention and
change in serum 25(OH)D by general linear models
(interaction present if p value<0.10). Logistic regression
was used for investigating changes in pain in upper legs
and functional limitations (dichotomized). MLwiN multi-
level modelling is an extension of multiple regression,
which is appropriate for analyzing hierarchically
structured data. In the present longitudinal data set, a
three-level hierarchy was defined, with the repeated
measurements (defined as level-1 units) grouped within
the individuals (who form the level-2 units), who were
grouped within GPs (level 3 units). An advantage of using
multilevel regression modelling compared to the tradition-
al repeated measurement approach is that the number of
measurements can vary between participants [29]. Addi-
tionally, differences between GPs can be modelled by a
multilevel structure. A multilevel model describes not
only underlying population trends in a response (the fixed
part of the model), but also models the variation around
this mean response due to the time of measurement and
due to individual differences (the random part) [30].
Because some participants changed vitamin D status after
screening, and were no longer vitamin D-deficient (serum
25(OH)D>25 nmol/l) at baseline, per-protocol analyses
were performed in which only participants with serum 25
(OH)D<25 nmol/l at baseline were included. All analyses




The study sample included 232 persons who participated
at baseline. Participants who did not provide a blood
sample (or whose sample was insufficient, n=17), whose
parents were both born in Europe (n=2), or who did not
answer the questionnaire at baseline (n=1) were excluded.
One person was excluded due to an exceptionally high
serum 25(OH)D level 3 months after baseline (25(OH)D=
240 nmol/l). This resulted in the inclusion of data on 211
participants in the intention-to-treat analysis. The baseline
serum 25(OH)D of 58 participants was above 25 nmol/l.
These subjects were included in the intention-to-treat, but
excluded from the per-protocol, analyses. Figure 1 shows
the flow of participants by type of analysis.
Baseline characteristics
The baseline characteristics of the 211 participants (53
men, 158 women) who were included in the intention-to-
treat analysis are shown in Table 1.T h e i rm e a n[ S D ]a g e
was 41.3 [11.6] years and their average BMI was 28.7
[6.2] kg/m
2. Almost 33% of the participants were obese
(≥30 kg/m
2). The baseline characteristics indicated a low
social-economic status of the population studied: 63.8%
h a dn op a i dj o b ,a n d5 3 . 4 %h a da c h i e v e da ne d u c a t i o n
level of primary school or less. Their mean serum 25(OH)
D was 22.5 [11.1] nmol/l and 31 (14.7%) had a serum 25
(OH)D of 12.5 nmol/l or less. Mean serum PTH was 9.6
[ 4 . 6 ]p m o l / l ,a n d5 5( 2 6 . 1 % )h a de l e v a t e dl e v e l so fP T H
(>11.0 pmol/l, upper reference limit), indicating certain
secondary hyperparathyroidism. Mean serum alkaline
phosphatase was 93 U/l when serum 25(OH)D was lower
t h a n1 2 . 5n m o l / la n d7 3 . 5U / lw h e ns e r u m2 5 ( O H ) Dw a s
876 Osteoporos Int (2011) 22:873–882higher than 25 nmol/l. The three intervention groups were
similar in demographic and prognostic variables, and
baseline values of outcome measurements. However, as
s h o w ni nF i g .1, participants who did not provide a blood
sample (or whose sample was insufficient) were more
often randomized to the sunlight group (p=0.003).
Short-term intervention effects: intention-to-treat
and per-protocol analyses
Sunlight exposure
According to the questionnaire, the median time spent
outside at baseline was 120 min in the three groups with no
change after 3 months. Hands and face were exposed to
sunlight in 98%, and about 40−50% of the subjects exposed
forearms to sunlight with no difference between the groups.
The sunlight diary was not completed by the subjects with
only two exceptions.
Biochemistry
Serum 25(OH)D level increased significantly in all inter-
vention groups at 3 months after baseline compared to
baseline level (Fig. 2). At both 3 and 6 months after
baseline, the serum 25(OH)D concentrations were signifi-
cantly higher in the supplementation groups than in the
advised sunlight group. No significant differences were
observed between the two supplementation groups. The
proportion of participants with serum 25(OH)D<25, 25−50
and 50−75 and >75 nmol/l at different time points is shown
in Table 2. With daily supplementation, serum 25(OH)D
was higher than 50 nmol/l in 73.7% of the participants.
Similar values were observed in 47.5% of the 100,000 IU
group and 22% of the sunlight group. At 6 months, these
percentages were lower than at 3 months. At 12 months, the
percentage of participants with vitamin D deficiency (serum
25(OH)D<25 nmol/l) was still lower than at baseline,
except for the sunshine group. A significant interaction was
observed between BMI and the increase of serum 25(OH)D
after supplementation. The increase was larger in the
100,000 IU group when BMI was lower than 25 kg/m
2
(mean increase with BMI<25, 25−30, and >30: 47, 30, and
21 nmol/l, respectively). The power was too low for a
stratified analysis.
Serum PTH concentrations decreased significantly in
all three intervention groups at 3 months after baseline.
At 6 months after baseline, PTH concentrations of both
supplementation groups were still significantly lower
compared to the sunlight group (100,000 IU, p=0.01;
800 IU, p=0.03). Per-protocol analyses showed the same
pattern of serum 25(OH)D and PTH concentrations.
However, at 3 months after baseline, a significant
difference in increase of serum 25(OH)D was observed
between both supplementation groups, in favor of the 800-
IU group.
At baseline, alkaline phosphatase was increased above
the upper reference level in 12 persons (10%), which points
to vitamin D-related bone disease (incipient or frank
232 persons were included and written informed consent 
obtained 
Randomization 
Vitamin D3: 800 IU/ per day    N= 77  Vitamin D3: 100,000 IU/ 3 months   N= 78  Advice: Sunlight exposure      N=77 
Excluded: 





Intention to treat   N= 74
Excluded:  
Baseline 25(OH)D>25nmol/l        N=22 
 
Post-hoc analyses:     N= 50
Excluded: 
Refused bloodtest at baseline       N=  1 
Both parents born in Europe       N=  2 
No questionnaire at baseline        N=  1 
Exceptional high serum 25-OHD (240 nmol/l)  N=  1 
 
Intention to treat  N=72  
Excluded: 





Intention to treat 
Excluded:  
Baseline 25(OH)D>25nmol/l        N=18 
 
Post-hoc analyses:     N= 56
Excluded:  
Baseline 25(OH)D>25nmol/l        N=18 
 
Post-hoc analyses:     N= 47 
N=65
Fig. 1 Flow diagram of the participants in the study
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phosphatase was increased in two persons (2%) only.
Serum alkaline phosphatase significantly decreased in all
treatment groups. It decreased from 80 to 71 U/l after
6 months in the 800 IU group, from 81 to 71 in the
100,000 IU group, and from 75 to 68 in the sunlight group.
Physical performance
During the active treatment period, no between-group
differences were observed in chair stand test and handgrip
strength. Similarly, no within-group differences were
observed over time.
Functional limitations
The three intervention groups reported significantly less
difficulty in daily life activities at 3 months after baseline
(p<0.05); this was only borderline significant (p=0.07) at
6 months after baseline. No between-group differences
were observed. The number of participants without any
functional limitations increased at 3 and 6 months com-
pared to baseline in all three groups.
Pain
Six months after baseline, lower odds for pain in upper legs
while sitting were observed compared to baseline. Howev-
er, no between-group differences were observed. Per-
protocol analysis showed no differences between groups
or within groups. The studied population reported a high
number of days per month with shoulder pain (approxi-
mately 15 times per month) and headache episodes
(approximately 118 times per year). During treatment, no
differences in shoulder pain were observed over time or
between groups. Remarkably, only within the group of
Table 1 Baseline characteristics of 211 participants, according to intervention, included in the intention-to-treat analysis
Total Capsules 800IU Capsules 100,000IU Sunshine
N 211 (100) 72 (34.1) 74 (35.1) 65 (30.8)
Gender (n=211)
Women 158 (74.9) 54 (34.2) 55 (34.8) 49 (31.0)
Age (years) (n=211) 41.3±11.4 40.5±10.8 41.9±11.6 41.5±12.0
Body mass index (kg/m
2)( n=211) 28.7±6.2 28.9±7.1 28.5±6.0 28.6±5.4
≥30: obese 69 (32.7) 23 (33.3) 21 (30.4) 25 (36.2)
Ethnicity (n=209)
Turkish 75 (35.9) 27 (36.0) 26 (34.7) 22 (29.3)
Moroccan 61 (29.2) 17 (27.9) 23 (37.7) 21 (33.4)
Suriname/Dutch Antilles/Curacao 33 (15.8) 16 (48.5) 10 (30.3) 7 (21.2)
African 12 (5.7) 3 (25.0) 5 (41.7) 4 (33.3)
Asian 28 (13.4) 8 (28.6) 10 (35.7) 10 (35.7)
Paid job (n=210)
No 134 (63.8) 50 (37.3) 43 (32.1) 41 (30.6)
Education (n=208)
No or lower education 111 (53.4) 35 (31.5) 40 (36.0) 36 (32.4)
Secondary school 44 (21.2) 14 (31.8) 13 (29.5) 17 (38.6)
Higher education: College—University 53 (25.5) 23 (43.4) 20 (37.7) 10 (18.9)
Smoking (n=210)
Yes 45 (21.5) 19 (42.2) 13 (28.9) 13 (28.9)
Drinking alcohol (n=209)
Yes 33 (15.8) 13 (39.4) 13 (39.4) 7 (21.2)
25(OH)D (nmol/l) (n=211) 22.45±11.1 22.4±8.9 21.8±12.3 23.3±12.0
PTH (pmol/l) (n=210) 9.6±4.6 9.1±5.2 10.1±4.4 9.5±4.3
Handgrip strength in kgf (n=210) 32.8±9.9 32.7±10.2 32.0±9.7 33.7±9.8
Chairtest in seconds (n=208) 14.0±5.2 13.8±4.4 13.9±5.3 14.3±5.8
Functional limitations (n=209) 4.3±3.8 4.7±3.8 4.1±3.6 4.2±4.0
Headache episode per year (n=209) 114.6±129.0 149.1±141.3 74.8±98.1 120.3±133.6
Values are numbers (%) or means ± standard deviations (SD)
878 Osteoporos Int (2011) 22:873–882800 IU per day did the number of headache episodes
decrease significantly over time. Per-protocol analyses
showed the same pattern.
Side effects
One side effect sometimes mentioned in the sunlight group was
skin itching after sunlight exposure without visible changes.
Side effects of the medication were not mentioned.
Long-term intervention effects: intention-to-treat
and per-protocol analyses
Biochemistry
At 12 months after baseline, higher serum 25(OH)D concen-
trations were observed in the supplementation groups com-
pared to the sunlight group (Fig. 2, Table 2). Within the
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Fig. 2 a Serum 25(OH)D, nmol/1 (median, 25th–75th percentiles) in the 800 IU/day group (A), the 100,000 IU/3 months group (B), and the
sunlight group (C). b Serum PTH, pmol/1 (median, 25th–75th percentiles) in groups A, B, and C
Table 2 Proportion (%) of participants with serum 25(OH)D<25, 25−50, 50−75, or >75 nmol/l at baseline, 3, 6, and 12 months according to
treatment group 800 IU/day, 100,000 IU/3 months or sunshine exposure
Group Serum 25(OH)D nmol/l T0% n T3% n T6% n T12% n
800 IU/day <25 66.2 47 7.1 4 11.5 6 37.2 16
25–50 33.8 24 19.3 11 30.8 16 51.2 22
50−75 −− 52.6 30 40.4 21 7.0 3
>75 − 21.1 12 17.3 9 4.7 2
100,000 IU/3 months <25 76.0 54 1.7 1 7.3 4 27.5 11
25−50 18.3 13 50.8 30 50.9 28 62.5 25
50−75 5.6 4 39.0 23 34.5 19 10.0 4
>75 −− 8.5 5 7.3 4 −−
Advised sunlight exposure <25 69.2 45 24.4 10 48.8 19 72.7 24
25−50 26.2 17 53.7 22 46.2 18 18.2 6
50−75 4.6 3 19.5 8 5.1 2 6.1 2
>75 −− 2.4 1 −− 3.0 1
The treatment was provided for 6 months, from April/May till October/November
Osteoporos Int (2011) 22:873–882 879Lower serum PTH concentrations were observed in supple-
mentation groups compared to the advised sunlight interven-
tion, which returned to baseline level. The difference was
borderline significant for the 800 IU group compared to the
advised sunlight group (p=0.065).
Physical performance
No differences were observed according to intention-to-
treat and per-protocol analyses in physical performance at
12 months after baseline compared to baseline, or between
groups.
Functional limitations
According to intention-to-treat analyses, all groups reported
less difficulty with daily life activities at 12 months after
baseline, compared to baseline. However, no differences
between interventions were observed.
Pain
Compared to baseline, at 12 months after baseline, no
differences were observed in odds for pain in upper legs,
days with shoulder pain, or number of headache episodes.
Discussion
As far as we know, this is the first randomized clinical trial
in which the effect of advised sunlight exposure was
compared with that of vitamin D supplementation. Sunlight
exposure is the natural way to increase serum 25(OH)D
concentrations, although the effects depend on the season
and on the area of exposed skin.
In our study, vitamin D supplementation appeared to
be necessary for adequate serum 25(OH)D concentrations
when treating vitamin D deficiency in non-western
immigrants living in the Netherlands. In the short term,
serum 25(OH)D levels increased and serum PTH levels
decreased in the advised sunlight group, but significant
differences were observed between the effect of oral
supplementation and sunlight exposure advice on both
serum 25(OH)D and PTH concentrations. In the long
term, serum 25(OH)D decreased and PTH levels again
increased to baseline level within the sunlight group,
while the supplementation groups were still better off at
12 months than at baseline.
Although Chel and colleagues have shown that ultraviolet
irradiation is as effective as vitamin D supplementation in
geriatric patients [31], exposure to sunlight itself was not very
effective in our study. This may be explained by the
pigmented skin of the study population, by limited skin
exposure due to skin-covering clothes, and by limited sunlight
exposure. According to The Norwegian Institute for Air
Research, it takes 2.4 times longer for persons with dark skin
(skin type 5) to synthesize the same amount of vitamin D than
for persons with skin type 2. For persons with skin type 6, this
will take four times longer. (http://nadir.nilu.no/~olaeng/fastrt/
VitD_quartMED.html). The skin surface exposed to sunlight
can be estimated at 5% (face and hands) to 15% (face,
forearms, and lower legs) in some individuals. Non-western
immigrants usually expose themselves less to sunshine than
born Dutch people due to cultural and religious habits. In fact,
a poor vitamin D status can be seen in pigmented persons
even in regions with abundant sunshine [32].
Although the participants received supplementation during
6 months, no further increase of serum 25(OH)D levels were
observed after 3 months, and PTH levels started to increase
after3months.Thiscouldindicateaproblemwithcompliance.
However, participants took 100,000 IU under supervision, and
exactly the same pattern is observed in the 800 IU group and
the sunlight group. This may indicate that supplementation
was inadequate. A dose-finding study in nursing home
residents studied with the same 25(OH)D assays showed that
serum 25(OH)D was higher than 50 nmol/l with vitamin D
600 IU/day in 90% of the participants [33]. This fact and the
decrease in serum 25(OH)D between 3 and 6 months (Fig. 2,
Table 2) indicate a compliance problem. Another point of
concern is the interaction of the increase of serum 25(OH)D
after supplementation with BMI, mainly in the 100,000 IU
group. Although this analysis should be considered explor-
atory, it may indicate that overweight and obese persons will
need higher supplementation doses. The negative relationship
between body fat percentage and serum 25(OH)D has been
reported in the Longitudinal Aging Study Amsterdam [34].
It is striking that PTH concentrations decreased most
in the100,000 IU group, although serum 25(OH)D
concentrations increased most in the 800 IU group. This
might be due to a higher peak concentration of serum
PTH in the 100,000 IU group. The mean serum alkaline
phosphatase decreased in all groups by about 20%. The
high alkaline phosphatase is a sign of high bone turnover
or disturbed mineralization due to vitamin D deficiency.
Besides serum 25(OH)D and PTH concentrations, several
clinical outcomes were studied. An improvement in
physical performance was not observed. Difficulties with
daily life activities decreased significantly, but no differ-
ences were observed between the interventions. This may
indicate that only a small improvement in vitamin D
status is needed to improve functional limitations.
Reported pain was not consistent over time or between
interventions: number of days with headache episodes
decreased significantly among participants in the 800-IU
intervention and reported pain in upper legs improved
significantly in the 100,000-IU intervention compared to
880 Osteoporos Int (2011) 22:873–882the advised sunlight intervention, but no improvement
was observed in shoulder pain.
The inconsistent clinical results can be explained by the
methodological restrictions of this study. There was no
placebo-control group as this was judged unethical in this
vitamin D-deficient population. Handgrip strength is known
to be positively correlated with both lower-extremity and
upper-body strength, and it appears to be a reliable test [35,
36]. The chair stand test is reliable and related to vitamin D
status [14], but both relationships have been established in
older populations. The impact of vitamin D deficiency on
muscle strength could be less in younger persons than in
older persons. In addition, the tests could not be sufficiently
discriminative in a younger population. The tests were
conducted in 11 different centers by different observers,
and this may also explain the lack of findings. A practical
limitation of this study is that the diaries of sunlight exposure
were poorly completed. Therefore, we only had a rough
indication of sunlight exposure during the summer from
questionnaires, but no measure of recent sun exposure.
Some remarkable results were found within the group of
800 IU per day: the number of headache episodes decreased
significantly over time. Strangely, the same pattern was not
observed in the 100,000-IU intervention. A high number of
dayswithheadacheepisodesper yearwas reportedpreviously
in vitamin D-deficient non-western immigrants in the Nether-
lands [8], but as far as we know, no relation between vitamin
D deficiency and headache has been observed before.
Attention should be paid to the combination of obesity and
vitamin D deficiency. Almost 33% of the studied population
was obese (BMI>30 kg/m
2). Obesity is associated with
reduced serum 25(OH)D and increased serum PTH concen-
trations [34, 37]. In obesity, vitamin D production in the skin
is not impaired, but after sun exposure, obese individuals
only show half of the increase of serum 25(OH)D compared
to non-obese individuals. It is suggested that the subcutane-
ous fat accumulation in obese people hampers the passage of
vitamin D formed in the skin into the blood circulation. In
addition, obese individuals have much lower surface-to-
volume ratio than normal-weight people. As a result, the
vitamin D produced in the skin is distributed over a larger
volume and should not be expected to produce the same
increment as in thinner individuals. Advice for sunlight
exposure does not appear to be an effective intervention in
obese people.
Besides the fact that sunlight was not very effective in
our study, and the higher dropout of participants in the
sunlight group (p=0.003), it can be questioned whether an
advice about sunlight exposure will be heard at all. When
promoting sunlight exposure, the strong and widespread
sun safety messages in the past few years should be taken
into account. Vitamin D supplementation is necessary, but
compliance may be a problem. Only 73% of 800 IU group
and 47% of the 100,000 IU group reached a serum 25(OH)
D level over 50 nmol/l, while the level of 75 nmol/l was
only reached by 21% of the 800 IU group. Therefore, the
efficacy of food fortification should also be evaluated, e.g.,
fortification of milk and other dairy products, orange juice
[38], bread [39], or vegetable oil.
Finally, the non-western immigrant population in the
Netherlands is rapidly aging (the number of non-western
immigrants of 65+ years increased from 28,408 in 2000 to
57,242 in 2007 (http://statline.cbs.nl/StatWeb/start.asp, selec-
tion population to origin and generation, accessed 15 August
2007)). They are exposed to multiple risk factors (aging,
lifestyle habits, skin pigmentation). Because of the fact that
vitamin D deficiency has a negative influence on health, more
effort should be spent on the early detection and treatment of
people with suboptimal concentrations of vitamin D.
An important limitation of the study is that it was done
in many practices with many observers, increasing the
variation on clinical outcome measurements. A second
limitation is the poor registration of sunshine exposure and
the poor compliance with it.
In conclusion, the results of this randomized controlled
trial show that vitamin D supplementation is much more
effective than advice for sunlight exposure when treating
vitamin D deficiency in non-western immigrants. The
vitamin D dose of 800 IU/day is not sufficient to increase
serum 25(OH)D over 50 nmol/l in more than 90%, which
probably is due to non-compliance in this group. Higher
doses may be needed in persons with higher BMI.
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